TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 réservoirs.
Cheng L., Wang Q., Li G., Banga R., Ma J., Yu H., Yasui F., Zhang Z., Pantaleo G., Perreau M., Zurawski S., Zurawski G., Levy Y., Su L..
Oct 1, 2018 | Publications